{"nctId":"NCT00876395","briefTitle":"Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer","startDateStruct":{"date":"2009-09-10","type":"ACTUAL"},"conditions":["Breast Cancer"],"count":719,"armGroups":[{"label":"Everolimus + Paclitaxel + Trastuzumab","type":"EXPERIMENTAL","interventionNames":["Drug: Everolimus","Drug: Trastuzumab","Drug: Paclitaxel"]},{"label":"Placebo + Paclitaxel + Trastuzumab","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Trastuzumab","Drug: Paclitaxel"]}],"interventions":[{"name":"Everolimus","otherNames":["RAD001"]},{"name":"Placebo","otherNames":[]},{"name":"Trastuzumab","otherNames":[]},{"name":"Paclitaxel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult Women (≥ 18 years old).\n* Histologically or cytologically confirmed invasive breast carcinoma with local recurrence or radiological evidence of metastatic disease.\n* Must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease.\n* HER2+ patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive).\n* Prior trastuzumab and/or chemotherapy (taxanes included) as neo-adjuvant or adjuvant treatment is allowed but should be discontinued \\> 12 months prior to randomization.\n* Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization. Patients treated with bisphosphonates at entry or who start bisphosphonates during study may continue this therapy during protocol treatment.\n* Documentation of negative pregnancy test.\n* Organ functions at time of inclusion.\n\nExclusion Criteria:\n\n* Prior mTOR inhibitors for the treatment of cancer.\n* Other anticancer therapy for locally advanced or metastatic breast cancer except for prior hormonal therapy.\n* Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites, etc).\n* Radiotherapy to ≥ 25% of the bone marrow within 4 weeks prior to randomization\n* History of central nervous system metastasis.\n* Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract.\n* Serious peripheral neuropathy.\n* Cardiac disease or dysfunction.\n* Uncontrolled hypertension.\n* HIV.\n* Pregnant,","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS) Per Investigators' Assessment Based on Local Radiology Review - Full Population","description":"PFS is defined as the time from the date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first. This was assessed in the full patient population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.95","spread":null},{"groupId":"OG001","value":"14.49","spread":null}]}]}]},{"type":"PRIMARY","title":"Progression-free Survival (PFS) Per Investigators' Assessment Based on Local Radiology Review - (Hormone Receptor (HR)-Negative Population","description":"PFS is defined as the time from the date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first. This was assessed in the HR-negative patient population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.27","spread":null},{"groupId":"OG001","value":"13.08","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) - Full Population","description":"OS is defined as the time from date of randomization to the date of death due to any cause. For patients with documented progression, survival follow up was performed either by telephone or clinic visit at least every 3 months. Additional survival updates were requested prior to interim or final analysis or prior to providing data to the health authorities. This was assessed in the full patient population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.56","spread":null},{"groupId":"OG001","value":"49.97","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) - HR-negative Population","description":"OS is defined as the time from date of randomization to the date of death due to any cause. For patients with documented progression, survival follow up was performed either by telephone or clinic visit at least every 3 months. Additional survival updates were requested prior to interim or final analysis or prior to providing data to the health authorities. This was assessed in the HR-negative patient population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.97","spread":null},{"groupId":"OG001","value":"41.63","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) - Full Population","description":"ORR is defined as the percentage of participants whose best overall response is either complete response (CR) or partial response (PR) according to RECIST. This was assessed in the full patient population. Complete response is achieved when all lesions evaluated at Baseline are absent at subsequent visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.1","spread":null},{"groupId":"OG001","value":"69.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) - HR-negative Population","description":"ORR is defined as the percentage of participants whose best overall response is either complete response (CR) or partial response (PR) according to RECIST. This was assessed in a subset of patients with Hormone Receptor Negative disease. Complete response is achieved when all lesions evaluated at Baseline are absent at subsequent visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","spread":null},{"groupId":"OG001","value":"70.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Benefit Rate (CBR) Equal to or Greater Than 24 Weeks - Full Population","description":"CBR is defined as the percentage of participants whose best overall response is either complete response (CR), a partial response (PR) or stable disease (SD) lasting for at least 24 weeks, according to RECIST. This was assessed in the full patient population. Complete response is achieved when all lesions evaluated at Baseline are absent at subsequent visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":null},{"groupId":"OG001","value":"81.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Benefit Rate (CBR) Equal to or Greater Than 24 Weeks - HR-negative Population","description":"CBR is defined as the percentage of participants whose best overall response is either complete response (CR), a partial response (PR) or stable disease (SD) lasting for at least 24 weeks, according to RECIST. This was assessed in a subset of patients with Hormone Receptor Negative disease. Complete response is achieved when all lesions evaluated at Baseline are absent at subsequent visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.8","spread":null},{"groupId":"OG001","value":"79.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Overall Response Based on Investigator - Full Population","description":"Time to overall response defined as the time between date of randomization until first documented response Complete reseponse (CR) or partial response (PR) ), according to RECIST. This was assessed in the full patient population and in a subset of patients with Hormone Receptor Negative disease. Complete response is achieved when all lesions evaluated at Baseline are absent at subsequent visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.10","spread":null},{"groupId":"OG001","value":"2.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Overall Response Based on Investigator - HR-negative Population","description":"Time to overall response defined as the time between date of randomization until first documented response Complete reseponse (CR) or partial response (PR) ), according to RECIST. This was assessed in the full patient population and in a subset of patients with Hormone Receptor Negative disease. Complete response is achieved when all lesions evaluated at Baseline are absent at subsequent visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.94","spread":null},{"groupId":"OG001","value":"1.97","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response (OR) - Full Population","description":"OR applies only to patients whose best OR was CR or PR. Start date = date of first documented response (CR or PR) and end date = date of documented response (CR or PR) and end date = date of event defined as the first documented progression or death due to underlying cause. Complete response is achieved when all lesions evaluated at Baseline are absent at subsequent visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null},{"groupId":"OG001","value":"63.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response (OR) - HR-negative Population","description":"OR applies only to patients whose best OR was CR or PR. Start date = date of first documented response (CR or PR) and end date = date of documented response (CR or PR) and end date = date of event defined as the first documented progression or death due to underlying cause. This was assessed in the HR-negative patient population. Complete response is achieved when all lesions evaluated at Baseline are absent at subsequent visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.4","spread":null},{"groupId":"OG001","value":"68.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Everolimus Blood Level Concentrations at Steady States for Everolimus","description":"Blood levels at steady states for everolimus 10 mg/day and 5 mg/day. Only valid samples are included. Some patients had dose reduction to 5 mg daily dose therefore the everolimus blood concentration for them have been summarized separately. Cycle = 28 days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.380","spread":"10.0169"},{"groupId":"OG001","value":"7.959","spread":"8.1546"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.485","spread":"22.1986"},{"groupId":"OG001","value":"23.449","spread":"10.4112"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.206","spread":"9.9821"},{"groupId":"OG001","value":"5.473","spread":"3.9690"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.494","spread":"21.5940"},{"groupId":"OG001","value":"20.329","spread":"7.9518"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.432","spread":"13.2782"},{"groupId":"OG001","value":"7.494","spread":"5.8503"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.947","spread":"28.0107"},{"groupId":"OG001","value":"22.192","spread":"10.9277"}]}]}]},{"type":"SECONDARY","title":"Paclitaxel Plasma Concentrations","description":"Blood levels at steady states for everolimus/placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.424","spread":"5.8645"},{"groupId":"OG001","value":"0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5159.338","spread":"15473.636"},{"groupId":"OG001","value":"4296.697","spread":"7431.0799"}]}]}]},{"type":"SECONDARY","title":"Trastuzumab Serum Concentrations","description":"Blood levels at steady states for everolimus/placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.606","spread":"9.6548"},{"groupId":"OG001","value":"29.180","spread":"12.1252"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.296","spread":"23.4635"},{"groupId":"OG001","value":"67.643","spread":"20.8852"}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Score - Full Population","description":"Time to definitive deterioration of the ECOG PS by one category of the score from baseline will be performed. Baseline is the last available assessment on or before randomization date. A deterioration is considered definitive if no improvements in the ECOG PS status is observed at a subsequent time of measurement during the treatment period following the time point where the deterioration is observed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.20","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Score - HR-negative Population","description":"Time to definitive deterioration of the ECOG PS by one category of the score from baseline will be performed. Baseline is the last available assessment on or before randomization date. A deterioration is considered definitive if no improvements in the ECOG PS status is observed at a subsequent time of measurement during the treatment period following the time point where the deterioration is observed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":173,"n":472},"commonTop":["Stomatitis","Diarrhoea","Alopecia","Cough","Fatigue"]}}}